YZYingye Zheng

Yingye Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yingye Zheng has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Tianxi Cai

    Department of Biostatistics, Harvard T. H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, USA

    11 shared publications
  • Tianxi Cai

    Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA

    5 shared publications
  • Patrick J. Heagerty

    Biostatistics and Biomathematics Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M2-B500, Seattle, WA 98109

    3 shared publications
  • Ziding Feng

    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109

    3 shared publications
  • Anna Sf Lok

    Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA

    2 shared publications
  • Layla Parast

    Department of Statistics and Data Sciences The University of Texas at Austin Austin Texas USA

    2 shared publications

Latest Publications

  • Open Access

    Evaluating longitudinal markers under two-phase study designs

    by Marlena Maziarz, Tianxi Cai, Li Qi, Anna S Lok, Yingye Zheng

    Little attention has been given to the design of efficient studies to evaluate longitudinal biomarkers. Measuring longitudinal markers on an entire cohort is cost prohibitive and, especially for rare outcomes such as cancer, may be infeasible. Thus, methods for evaluation of longitudinal biomarkers using efficient and cost-effective study designs are needed. Case cohort (CCH) and nested case–control (NCC) studies allow investigators to evaluate biomarkers rigorously and at reduced cost, with only a small loss in precision. In this article, we develop estimators of several measures to evaluate the accuracy and discrimination of predicted risk under CCH and NCC study designs. We use double inverse probability weighting (DIPW) to account for censoring and sampling bias in estimation and inference procedures. We study the asymptotic properties of the proposed estimators. To facilitate inference using two-phase longitudinal data, we develop valid resampling-based variance estimation procedures under CCH and NCC. We evaluate the performance of our estimators under CCH and NCC using simulation studies and illustrate them on a NCC study within the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) clinical trial. Our estimators and inference procedures perform well under CCH and NCC, provided that the sample size at the time of prediction (effective sample size) is reasonable. These methods are widely applicable, efficient, and cost-effective and can be easily adapted to other study designs used to evaluate prediction rules in a longitudinal setting.

  • Calibrating Variations in Biomarker Measures for Improving Prediction with Time-to-event Outcomes

    by Cheng Zheng, Yingye Zheng

    Novel biologic markers have been used to predict clinical outcomes of many diseases. One specific feature of biomarkers is that they often are measured with variations due to factors such as sample preparation and specific laboratory process. Statistical methods have been proposed to characterize the effects of underlying error-free quantity in association with an outcome, yet the impact of measurement errors in terms of prediction has not been well studied. We focus in this manuscript on using biomarkers for predicting an individual’s future risk for survival outcome. In the setting where replicates of error-prone biomarkers are available in a ‘training’ population and risk projection is applied to individuals in a ‘prediction’ population, we propose two-step measurement-error-corrected estimators of absolute risks. We conducted numerical studies to evaluate the predictive performance of the proposed and routine approaches under various assumptions about the measurement error distributions to pinpoint situations when correction of measurement errors might be necessary. We studied the asymptotic properties of the proposed estimators. We applied the estimators to a liver cancer biomarker study to predict risk of liver cancer incidence using age and a novel biomarker, \(\alpha \)-Fetoprotein.

  • Open Access

    Study Design Considerations for Cancer Biomarker Discoveries

    by Yingye Zheng

    Background: Biomarker discovery studies have generated an array of omic data; however, few novel biomarkers have reached clinical use. Guidelines for rigorous study designs are needed. Content: Biases frequently occur during sample selection, outcome ascertainment, or unblinded sample handling and the assaying process. The principles of a prospective specimen collection and retrospective blinded evaluation design can be adapted to mitigate various sources of biases in discovery. We recommend establishing quality biospecimen repositories using matched 2-phase designs to minimize biases and maximize efficiency. We also highlight the importance of taking the clinical context into consideration in both sample selection and power calculation for discovery studies. Summary: Biomarker discovery research should follow rigorous design principles in sample selection to avoid biases. Consideration of clinical application and the corresponding biomarker performance characteristics in study designs will lead to a more fruitful discovery study.


  • Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs

    by Dandan Liu, Tianxi Cai, Anna Lok, Yingye Zheng

    Large prospective cohort studies of rare chronic diseases require thoughtful planning of study designs, especially for biomarker studies when measurements are based on stored tissue or blood specimens. Two-phase designs, including nested case–control and case-cohort sampling designs, provide cost-effective strategies for conducting biomarker evaluation studies.Existing literature for biomarker assessment under two-phase designs largely focuses on simple inverse probability weighting (IPW) estimators. Drawing on recent theoretical development on the maximum likelihood estimators for relative risk parameters in two-phase studies, we propose nonparametric maximum likelihood-based estimators to evaluate the accuracy and predictiveness of a risk prediction biomarker under both types of two-phase designs. In addition, hybrid estimators that combine IPW estimators and maximum likelihood estimation procedure are proposed to improve efficiency and alleviate computational burden. We derive large sample properties of proposed estimators and evaluate their finite sample performance using numerical studies. We illustrate new procedures using a two-phase biomarker study aiming to evaluate the accuracy of a novel biomarker, des-γ-carboxy prothrombin, for early detection of hepatocellular carcinoma. Supplementary materials for this article are available online.


  • Open Access

    Improving efficiency in biomarker incremental value evaluation under two-phase designs

    by Yingye Zheng, Marshall Brown, Anna Lok, Tianxi Cai

    Cost-effective yet efficient designs are critical to the success of biomarker evaluation research. Two-phase sampling designs, under which expensive markers are only measured on a subsample of cases and noncases within a prospective cohort, are useful in novel biomarker studies for preserving study samples and minimizing cost of biomarker assaying. Statistical methods for quantifying the predictiveness of biomarkers under two-phase studies have been proposed [Biostatistics13 (2012) 89–100, Biometrics68 (2012) 1219–1227]. These methods are based on a class of inverse probability weighted (IPW) estimators where weights are “true” sampling weights that simply reflect the sampling strategy of the study. While simple to implement, existing IPW estimators are limited by lack of practicality and efficiency. In this manuscript, we investigate a variety of two-phase design options and provide statistical approaches aimed at improving the efficiency of simple IPW estimators by incorporating auxiliary information available for the entire cohort. We consider accuracy summary estimators that accommodate auxiliary information in the context of evaluating the incremental values of novel biomarkers over existing prediction tools. In addition, we evaluate the relative efficiency of a variety of sampling and estimation options under two-phase studies, shedding light on issues pertaining to both the design and analysis of biomarker validation studies. We apply our methods to the evaluation of a novel biomarker for liver cancer risk conducted with a two-phase nested case control design [Gastroenterology138 (2010) 493–502].


  • On Longitudinal Prediction with Time-to-Event Outcome: Comparison of Modeling Options

    by Marlena Maziarz, Patrick Heagerty, Tianxi Cai, Yingye Zheng

    Long‐term follow‐up is common in many medical investigations where the interest lies in predicting patients’ risks for a future adverse outcome using repeatedly measured predictors over time. A key quantity is the likelihood of developing an adverse outcome among individuals who survived up to time s given their covariate information up to time s. Simple, yet reliable, methodology for updating the predicted risk of disease progression using longitudinal markers remains elusive. Two main approaches have been considered in the literature. One approach, based on joint modeling (JM) of failure time and longitudinal covariate process (Tsiatis and Davidian, 2004), derives such longitudinal predictive probability from the joint probability of a longitudinal marker and an event at a given time. A second approach, the partly conditional (PC) modeling (Zheng and Heagerty, 2005), directly models the predictive probability conditional on survival up to a landmark time and information accrued by that time. In this article, we propose new PC models for longitudinal prediction that are more flexible than joint modeling and improve the prediction accuracy over existing PC models. We provide procedures for making inference regarding future risk for an individual with longitudinal measures up to a given time. In addition, we conduct simulations to evaluate both JM and PC approaches in order to provide practical guidance on modeling choices. We use standard measures of predictive accuracy adapted to our setting to explore the predictiveness of the two approaches. We illustrate the performance of the two approaches on a dataset from the End Stage Renal Disease Study (ESRDS).


  • Assessing Incremental Value of Biomarkers with Multi-phase Nested Case-control Studies

    by Qian M. Zhou, Yingye Zheng, Lori B. Chibnik, Elizabeth W. Karlson, Tianxi Cai

    Summary: Accurate risk prediction models are needed to identify different risk groups for individualized prevention and treatment strategies. In the Nurses’ Health Study, to examine the effects of several biomarkers and genetic markers on the risk of rheumatoid arthritis (RA), a three-phase nested case-control (NCC) design was conducted, in which two sequential NCC subcohorts were formed with one nested within the other, and one set of new markers measured on each of the subcohorts. One objective of the study is to evaluate clinical values of novel biomarkers in improving upon existing risk models because of potential cost associated with assaying biomarkers. In this paper, we develop robust statistical procedures for constructing risk prediction models for RA and estimating the incremental value (IncV) of new markers based on three-phase NCC studies. Our method also takes into account possible time-varying effects of biomarkers in risk modeling, which allows us to more robustly assess the biomarker utility and address the question of whether a marker is better suited for short-term or long-term risk prediction. The proposed procedures are shown to perform well in finite samples via simulation studies.


  • Adopting nested case–control quota sampling designs for the evaluation of risk markers

    by Yingye Zheng, Tianxi Cai, Margaret S. Pepe

    Two-phase study methods, in which more detailed or more expensive exposure information is only collected on a sample of individuals with events and a small proportion of other individuals, are expected to play a critical role in biomarker validation research. One major limitation of standard two-phase designs is that they are most conveniently employed with study cohorts in which information on longitudinal follow-up and other potential matching variables is electronically recorded. However for many practical situations, at the sampling stage such information may not be readily available for every potential candidates. Study eligibility needs to be verified by reviewing information from medical charts one by one. In this manuscript, we study in depth a novel study design commonly undertaken in practice that involves sampling until quotas of eligible cases and controls are identified. We propose semiparametric methods to calculate risk distributions and a wide variety of prediction indices when outcomes are censored failure times and data are collected under the quota sampling design. Consistency and asymptotic normality of our estimators are established using empirical process theory. Simulation results indicate that the proposed procedures perform well in finite samples. Application is made to the evaluation of a new risk model for predicting the onset of cardiovascular disease.


  • Sa2001 Analysis of the Expression and Clinical Significance of Kallikrein-Related Peptidases 8 and 14 (Klk8 & Klk14) in Colon Cancer

    by Dimitrios Kypraios, Marshall D. Brown, Yingye Zheng, Marina Devetzi, Stefanos P Bassioukas, Panagiotis Katerinis, Apostolos Malachias, Dimitrios Xinopoulos, Niki Arnogiannaki, Maroulio Talieri